Publications

European journal of cancer (Oxford, England : 1990)

The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.

18-06-2026

Cancer cell

Targeting tumor-intrinsic STK40 induces immune vulnerability and drives T cell reinvigoration.

28-05-2026

Clinical cancer research : an official journal of the American Association for Cancer Research

PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results.

15-05-2026

Nature protocols

Inducible CRISPR-Cas9 screening platform to interrogate non-proliferative cellular states.

01-05-2026

Trends in immunology

Exploiting immunogenic cell death to promote antitumor immunity.

16-04-2026

Cell

CLIM-TIME links genetic cancer drivers to immune landscapes.

05-03-2026

Journal of experimental & clinical cancer research : CR

CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer.

22-01-2026

ESMO open

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial.

01-12-2025

Nature cancer

European cancer research requires renewed urgency.

01-12-2025

Proceedings of the National Academy of Sciences of the United States of America

CRISPR screens identify the ATPase VCP as a druggable therapeutic vulnerability in cholangiocarcinoma.

30-09-2025

Molecular oncology

A single gene mutation predicts response to immune checkpoint blockade in ovarian clear cell carcinoma.

01-09-2025

Trends in cancer

Prospects for understanding and exploiting the consequences of hyperactivation lethality.

01-07-2025

Proceedings of the National Academy of Sciences of the United States of America

Reply to Mishima et al.: MALT1 modulates GPX4 expression by regulating its stability.

20-05-2025

Developmental cell

DYRK1A-TGF-β signaling axis determines sensitivity to OXPHOS inhibition in hepatocellular carcinoma.

19-05-2025

Cell death and differentiation

Senolysis by ABT-263 is associated with inherent apoptotic dependence of cancer cells derived from the non-senescent state.

01-05-2025

The Journal of pathology

Afadin loss induces breast cancer metastasis through destabilisation of E-cadherin to F-actin linkage.

01-05-2025

Cell death and differentiation

Apoptotic priming in senescence predicts specific senolysis by quantitative analysis of mitochondrial dependencies.

01-05-2025

Gut

Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges.

07-04-2025

Signal transduction and targeted therapy

Hepatocellular carcinoma: signaling pathways and therapeutic advances.

07-02-2025

Proceedings of the National Academy of Sciences of the United States of America

Deciphering the role of the MALT1-RC3H1 axis in regulating GPX4 protein stability.

07-01-2025

Proceedings of the National Academy of Sciences of the United States of America

An antibiotic that mediates immune destruction of senescent cancer cells.

24-12-2024

Cancer cell

Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy.

09-12-2024

Signal transduction and targeted therapy

Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial.

09-12-2024

Nature reviews. Cancer

Cancer drug-tolerant persister cells: from biological questions to clinical opportunities.

01-10-2024

Molecular oncology

A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm.

01-10-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

01-08-2024

Cancer discovery

Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy.

01-07-2024

Cancer cell

The case for therapeutic overactivation of oncogenic signaling as a potential cancer treatment strategy.

10-06-2024

Gastroenterology

Dual Inhibition of CDK4/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs.

01-06-2024

EMBO reports

The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing.

01-05-2024

Cell

Embracing cancer complexity: Hallmarks of systemic disease.

28-03-2024

Cell reports. Medicine

Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse.

19-03-2024

Proceedings of the National Academy of Sciences of the United States of America

Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers.

27-02-2024

Cancer cell

Precision treatment in advanced hepatocellular carcinoma.

12-02-2024

Cell research

LICOB: a powerful organoid platform for drug discovery.

01-01-2024

BJR open

How to 19F MRI: applications, technique, and getting started.

13-11-2023

Molecular oncology

Molecular Oncology and the EACR: new partners in communicating and supporting cancer research.

01-06-2023

Molecular oncology

Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.

01-06-2023

Clinical and translational medicine

Drug-drug synthetic lethality to combat cancer: From bench to bedside.

01-05-2023

Angiogenesis

Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy.

01-05-2023

Nature reviews. Gastroenterology & hepatology

Evolving therapeutic landscape of advanced hepatocellular carcinoma.

01-04-2023

Molecular oncology

More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics.

01-03-2023

Nature reviews. Drug discovery

Rational combinations of targeted cancer therapies: background, advances and challenges.

01-03-2023

Nature cancer

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF^V600E colorectal tumors.

01-02-2023

EBioMedicine

Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer.

01-01-2023

Cell research

RASON, a new player in cancer's Premier League.

01-01-2023

Molecular cancer therapeutics

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.

02-12-2022

Cell reports. Medicine

Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer.

15-11-2022

Nature cancer

cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis.

01-11-2022

PloS one

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.

07-09-2022

The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.

Targeting tumor-intrinsic STK40 induces immune vulnerability and drives T cell reinvigoration.

PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results.

Inducible CRISPR-Cas9 screening platform to interrogate non-proliferative cellular states.

Exploiting immunogenic cell death to promote antitumor immunity.

CLIM-TIME links genetic cancer drivers to immune landscapes.

CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer.

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial.

European cancer research requires renewed urgency.

CRISPR screens identify the ATPase VCP as a druggable therapeutic vulnerability in cholangiocarcinoma.

A single gene mutation predicts response to immune checkpoint blockade in ovarian clear cell carcinoma.

Prospects for understanding and exploiting the consequences of hyperactivation lethality.

Reply to Mishima et al.: MALT1 modulates GPX4 expression by regulating its stability.

DYRK1A-TGF-β signaling axis determines sensitivity to OXPHOS inhibition in hepatocellular carcinoma.

Senolysis by ABT-263 is associated with inherent apoptotic dependence of cancer cells derived from the non-senescent state.

Afadin loss induces breast cancer metastasis through destabilisation of E-cadherin to F-actin linkage.

Apoptotic priming in senescence predicts specific senolysis by quantitative analysis of mitochondrial dependencies.

Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges.

Hepatocellular carcinoma: signaling pathways and therapeutic advances.

Deciphering the role of the MALT1-RC3H1 axis in regulating GPX4 protein stability.

An antibiotic that mediates immune destruction of senescent cancer cells.

Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy.

Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial.

Cancer drug-tolerant persister cells: from biological questions to clinical opportunities.

A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm.

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy.

The case for therapeutic overactivation of oncogenic signaling as a potential cancer treatment strategy.

Dual Inhibition of CDK4/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs.

The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing.

Embracing cancer complexity: Hallmarks of systemic disease.

Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse.

Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers.

Precision treatment in advanced hepatocellular carcinoma.

LICOB: a powerful organoid platform for drug discovery.

How to 19F MRI: applications, technique, and getting started.

Molecular Oncology and the EACR: new partners in communicating and supporting cancer research.

Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.

Drug-drug synthetic lethality to combat cancer: From bench to bedside.

Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy.

Evolving therapeutic landscape of advanced hepatocellular carcinoma.

More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics.

Rational combinations of targeted cancer therapies: background, advances and challenges.

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors.

Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer.

RASON, a new player in cancer's Premier League.

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.

Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer.

cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis.

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.

This site uses cookies

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF^V600E colorectal tumors.